ArticleRNA (New York, N.Y.)2019
Regulation of cyclic oligoadenylate synthesis by the
Article in RNA (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Cas10 residues lining the target RNA binding channel regulate interference by distinguishing cognate target RNA from mismatched targets.RNA biology · 2026Article
- Craspase Protease Activation Is Sensitive to Oncogenic Single-Nucleotide RNA Mismatches.ACS chemical biology · 2026Article
- Structural plasticity enables broad cAn binding and dual activation of CRISPR-associated ribonuclease Cdn1.Nucleic acids research · 2026Article
- Manipulation of the nucleotide pool in human, bacterial and plant immunity.Nature reviews. Immunology · 2026Review
- TIGR-Tas and the Expanding Universe of RNA-Guided Genome Editing Systems: A New Era Beyond CRISPR-Cas.Genes · 2025Review
- AcrIIIA1 is a protein-RNA anti-CRISPR complex that targets core Cas and accessory nucleases.Nucleic acids research · 2024Article
- Molecular basis for cA6 synthesis by a type III-A CRISPR-Cas enzyme and its conversion to cA4 production.Nucleic acids research · 2024Article
- Bioinformatic analysis of type III CRISPR systems reveals key properties and new effector families.Nucleic acids research · 2024Article
- Retention of the RNA ends provides the molecular memory for maintaining the activation of the Csm complex.Nucleic acids research · 2024Article
- Genetic Engineering of Therapeutic Phages Using Type III CRISPR-Cas Systems.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Sequence-specific capture and concentration of viral RNA by type III CRISPR system enhances diagnostic.Nature communications · 2022Article
- Article
- Molecular basis of cyclic tetra-oligoadenylate processing by small standalone CRISPR-Cas ring nucleases.Nucleic acids research · 2022Article
- The effect of crRNA-target mismatches on cOA-mediated interference by a type III-A CRISPR-Cas system.RNA biology · 2022Article
- Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector.Nucleic acids research · 2021Article
- Structural basis of cyclic oligoadenylate degradation by ancillary Type III CRISPR-Cas ring nucleases.Nucleic acids research · 2021Article
- Type III CRISPR-Cas Systems: Deciphering the Most Complex Prokaryotic Immune System.Biochemistry. Biokhimiia · 2021Review
- Virus detection via programmable Type III-A CRISPR-Cas systems.Nature communications · 2021Article
- Intrinsic signal amplification by type III CRISPR-Cas systems provides a sequence-specific SARS-CoV-2 diagnostic.Cell reports. Medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
CRISPR-Cas systems are a class of adaptive immune systems in prokaryotes that use small CRISPR RNAs (crRNAs) in conjunction with CRISPR-associated (Cas) nucleases to recognize and degrade foreign nucleic acids. Recent studies have revealed that Type III CRISPR-Cas systems synthesize second messenger molecules previously unknown to exist in prokaryotes, cyclic oligoadenylates (cOA). These molecules activate the Csm6 nuclease to promote RNA degradation and may also coordinate additional cellular responses to foreign nucleic acids. Although cOA production has been reconstituted and characterized for a few bacterial and archaeal Type III systems, cOA generation and its regulation have not been explored for the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.